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Most malignant tumors disrupt the p53 signaling pathway in order to grow and survive. Although 
many genes in addition to p53 are mutated in tumors, recent studies by Ventura et al. (2007) 
and Xue et al. (2007) suggest that restoring p53 function alone is sufficient to cause regression 
of several different tumor types in mice and thus might represent a potent therapeutic strategy 
to treat certain human cancers. Martins et al. (2006) also demonstrate that restoration of p53 
activity results in tumor regression but add the sobering caveat that tumors may be able to 
quickly generate resistance by finding other ways to disrupt the p53 pathway.The p53 tumor suppressor protein is a potent roadblock 
to tumor development. People who carry one altered p53 
gene in their germline have an extraordinarily high prob-
ability of developing a tumor. Indeed, most human can-
cers contain either mutations in the p53 gene that gen-
erate a dysfunctional or absent protein or have altered 
expression of other gene products that disrupt p53 
function (Vousden and Prives, 2005). Consistent with 
the demonstrated role of p53 in helping cells to respond 
to DNA damage and other cellular stresses, tumors 
lacking p53 demonstrate significant genetic instability 
and often contain markedly abnormal genomes. Given 
the many genetic changes that are present in tumors, it 
has been reasonable to wonder whether “fixing” a sin-
gle change would be sufficient to curb tumor growth or 
progression. Despite the potent antitumor properties 
of p53, it is not clear whether its loss simply facilitates 
the genetic changes that contribute to tumor develop-
ment or whether tumor growth is dependent on keep-
ing the p53 pathway turned off permanently. Three 
recent papers, one in Cell (Martins et al. 2006) and two 
in Nature (Ventura et al., 2007; Xue et al., 2007), report 
the same striking conclusion: restoration of p53 func-
tion in established tumors (including lymphomas, sarco-
mas, and hepatocellular carcinomas) causes regression 
of tumors in vivo and could represent an effective new 
approach to treating cancer.
Tumor “Addiction”
With the many genetic changes noted in tumors, it has 
not been clear whether tumors remain dependent on 
any single change for their continued growth and pro-
gression. It is conceivable that any given genetic change 
may be required for a particular step in the process of 
malignant transformation but that once the tumor has 
progressed beyond that particular stage, that genetic 
alteration would no longer be required to maintain the 
transformed phenotype. Such a scenario would suggest 
that targeting single abnormalities in tumors might be 
insufficient to control tumor growth and progression. However, work in several mouse models suggests that 
tumors develop a dependence on growth-promoting 
oncogenic changes, such as activating mutations in the 
Myc or Ras oncogenes (Felsher and Bishop, 1999; Chin 
et al., 1999). This dependence has been termed “onco-
gene addiction” (Weinstein, 2002), because tumors 
regress when these activating mutations are experimen-
tally eliminated from the tumors.
Mutations in tumors include those that activate 
growth-promoting genes and those that inactivate gene 
products that limit growth or enhance cell death. The 
p53 protein, perhaps the most intensely studied of such 
“tumor suppressor” gene products, normally aids the cell 
in responding to a variety of different cellular stresses 
(Figure 1). Once activated by a stress, p53 either induces 
cell-cycle arrest or facilitates programmed cell death 
(apoptosis). It accomplishes this either through its role 
as a transcription cofactor or perhaps by carrying out 
other cellular functions. The “choice” between cell death 
or growth arrest depends on the cell type and cellular 
environment. Loss of p53 function probably contributes 
to tumor progression through a combination of increased 
genetic instability, loss of growth-arresting signals, and 
inappropriate cell survival. If the primary reason that p53 
loss contributes to tumor development is the generation 
of increased genetic instability, then p53 dysfunction 
might act as a “hit-and-run” mutation. In other words, 
p53 dysfunction would contribute to tumor development 
because it increases the rate of genetic mutations, but 
p53 dysfunction may not be required for tumor mainte-
nance once the genetic changes that create the trans-
formed phenotype are in place. However, perhaps not 
unexpectedly, the three new studies all demonstrate 
that like “oncogene addiction,” tumors remain addicted 
to the loss of p53 function. Each paper uses a different 
mouse-tumor model, and each brings unique insights to 
the process.
The laboratory of Tyler Jacks (Ventura et al., 2007) 
used an elegant genetic manipulation to make mice in 
which p53 was not expressed in any tissues because Cell 128, March 9, 2007 ©2007 Elsevier Inc. 837
Figure 1. Pathways to p53 Activation
In unstressed cells, p53 protein is present at 
low levels and is relatively inactive. During the 
process of malignant transformation in human 
cells, a number of different changes occur in 
the cells that result in induction and activation 
of the p53 protein. The Atm, Atr, and Arf pro-
teins play important roles in signaling to p53 in 
the presence of these different stimuli. Once 
activated, p53 suppresses tumor progression 
by restricting growth, survival, and/or genetic 
instability of the aspiring tumor cells. Muta-
tions in p53 or the p53 pathway can release 
these tumor-suppressive effects and permit 
growth and progression of the tumor mass. 
Although many genetic changes occur in tu-
mor cells, the three papers discussed here all 
demonstrate that restoration of p53 function is 
sufficient to blunt tumor growth. Given the va-
riety of mechanisms by which tumors disrupt 
p53 pathway function, different approaches 
would likely be needed to restore p53 function 
in different settings. Any attempt to restore 
p53 function in tumors in vivo would be limited 
by the ability of tumor cells to simply mutate 
other steps in the p53 pathway as a mecha-
nism of resistance to such p53 therapy.of the insertion of a STOP cassette in front of the 
gene. However, they could restore p53 function by 
removal of the STOP cassette following activation of a 
tamoxifen-inducible Cre recombinase. In this system, 
the mice develop spontaneous or irradiation-induced 
tumors with a high frequency because of the lack of 
p53 expression, and p53 can be restored at will by 
administration of tamoxifen. One unique aspect of this 
system is that the absence of p53 expression causes 
the mice to develop both lymphomas and sarcomas, 
allowing exploration of the effects of p53 restoration 
in at least two different tumor types in a single model 
system. After allowing the tumors to grow to sizes eas-
ily detected by MRI imaging, the investigators treated 
the mice with tamoxifen, thus activating the nuclear 
activity of the Cre recombinase, which then cuts 
out the STOP cassette and restores p53 expression 
throughout the mouse. Restoration of p53 expression 
caused significant, sometimes complete, regression 
of both lymphomas and sarcomas. Interestingly, p53 
appeared to work by different mechanisms in the two 
different tumor types. Its re-expression induced apop-
totic cell death in the lymphomas, whereas the sarco-
mas underwent cell-cycle arrest with signs of cellular 
senescence. Notably, the re-expression of p53 did not 
cause toxicity in normal mouse tissues, thus demon-
strating that the tumor cells contain signals that acti-
vate the p53 pathway, leading to its growth suppres-
sive or death-promoting effects selectively in tumor 
cells. Cell death is an irreversible state, and cellular 
senescence may also be irreversible. However, the in 
vivo permanence of the antitumor effects of p53 res-
toration was not explored in this model, thus leaving 
open the question of whether this would be an effec-
tive therapeutic intervention.838 Cell 128, March 9, 2007 ©2007 Elsevier Inc.A mouse model of hepatocellular carcinoma was used 
by Scott Lowe’s laboratory (Xue et al., 2007) to address 
very similar questions. In this system, purified embry-
onic liver cells are transformed by introduction of an 
activated Hras oncogene, and p53 expression is down-
regulated using a doxycycline-repressible short hairpin 
RNA directed against p53. In this scenario, p53 is sup-
pressed in the absence of doxycycline, and expression 
is restored when doxycycline is added. The investigators 
also transduced the cells with a fluorescent (GFP) marker 
and/or luciferase so that they could follow the tumor size 
in vivo with imaging. Injection of the Hras-expressing, 
p53-defective cells into immunodeficient (athymic) mice 
resulted in rapid growth of invasive hepatocarcinomas. 
Once the tumors were established, the investigators 
could restore p53 function by the addition of doxycy-
cline. Established tumors became virtually undetectable 
within 12 days of doxycycline treatment, and even tran-
sient re-expression of p53 after four days of doxycycline 
treatment caused complete tumor regression. Thus, 
once activated, the p53-induced tumor suppression 
seemed irreversible.
Similar to the observations of Ventura et al. (2007) in 
the mouse sarcoma model, Xue et al. (2007) found that 
p53 induction in their hepatocarcinoma model led to 
growth arrest with senescence rather than apoptotic cell 
death. These observations are consistent with reports 
that the cell-cycle suppressive properties of p53 are an 
important part of its tumor-suppressive activities (Liu et 
al., 2004). The irreversible effects of transient p53 induc-
tion caused Xue et al. (2007) to explore non-cell-autono-
mous mechanisms of tumor growth arrest, and they pro-
vide evidence for a role of the innate immune system. 
Inhibition of innate immunity through chemical, anti-
body, or genetic means reduced tumor regression fol-
lowing p53 restoration. The authors do point out that the 
athymic nude mice used for the initial studies may lack 
functional B and T cells, but they retain innate immune 
function. Interestingly, although the innate immune sys-
tem seemed to be important for regression of the tumor 
mass, it was not required for the inhibition of tumor cell 
growth. Demonstration of a role for this component of 
the immune system in tumor regression following p53 
restoration is a unique aspect of this paper compared 
to the other two, but the importance of this regression 
in tumor control and tumor shrinkage is not yet clear. 
The tumor mass might remain but might have been per-
manently arrested. The suggestion that even transient 
restoration of p53 may be sufficient for prolonged tumor 
control, at least in this tumor type, is a potentially impor-
tant insight from this model.
In their recent study in Cell, Gerald Evans and his team 
(Martins et al., 2006) used the Eµ-myc mouse model, 
which recapitulates human Burkitt’s lymphoma/leuke-
mia (Christophorou et al., 2005), as the backbone to ask 
questions about the effects of modulation of the p53 
pathway on various aspects of tumor biology. Using this 
system (Martins et al., 2006), they addressed the question 
of whether restoration of p53 expression in established 
tumors would lead to tumor regression. Their model sys-
tem uses a p53 knockin model in which the normal p53 
gene is replaced by a chimeric p53 protein containing 
an estrogen receptor (ER) domain linked to the wild-type 
p53 sequence. In this situation, the p53 protein is made 
but is retained in the cytoplasm in a nonfunctional state; 
addition of 4-hydroxytamoxifen (4-OHT) then drives 
transport of the p53 protein into the nucleus, where it 
can exert its tumor-suppressive activities. Eµ-myc mice 
were generated that contained one wild-type p53 allele 
and one p53-inducible allele. The mice rapidly develop 
B cell lymphoid malignancies as they lose their wild-type 
p53 allele and assume a p53 null state. Adding 4-OHT 
to the tumor cells from these mice in vitro activated the 
function of the remaining p53 allele and inhibited cellular 
growth and survival. Transplantation of these tumor cells 
into syngeneic mice resulted in rapid tumor growth and 
100% death of the mice in less than four weeks; addi-
tion of 4-OHT markedly increased tumor cell death and 
significantly prolonged survival of the mice.
Although survival of the tumor-bearing mice was defi-
nitely prolonged after a 7 day pulse of 4-OHT treatment, 
the mice eventually succumbed to the tumors. The tumor 
cells from all of these 4-OHT-treated relapsing mice had 
become resistant to p53 through disruption of the p53 
signaling pathway, either by loss of p19ARF expression or 
by deletion of the p53 ER allele. This potentially impor-
tant observation is unique among these three studies 
and raises the specter that even if p53 function could 
be restored to tumors in vivo that any therapeutic ben-
efit might be short lived, because the tumor could find 
other ways to inactivate the p53 pathway. One limitation 
of this pessimistic, but perhaps predictable, conclusion 
is that only a 7 day pulse of p53 activity was used in these experiments. It is possible that persistent restora-
tion of p53 function would not be as susceptible to the 
generation of resistance. It is worth noting that Xue et al. 
(2007) observed permanent inhibition of tumor growth 
in their hepatocarcinoma model even after only a 4 day 
activation of p53 function. Given that their tumor sys-
tem appeared to depend on cellular senescence and the 
immune system for tumor control, whereas p53 activa-
tion in the Eµ-myc system appears to work via induction 
of apoptotic cell death, there may be tumor-type spe-
cificity in the practical effectiveness of this therapeutic 
strategy. Interestingly, in the Eµ-myc tumor cells that had 
inactivated the p53 pathway via loss of p19ARF expres-
sion, the p53 protein was still functional and could still 
be induced by irradiation. Thus, addition of a p53-acti-
vating stimulus, such as irradiation or chemotherapy, 
might make the strategy of p53 functional restoration in 
tumors more therapeutically effective.
Relevance for Human Cancer Therapy
Studies of all three mouse tumor model systems yielded 
the same conclusion about the tumor-reducing effects of 
p53 restoration in tumor masses. Should we be encour-
aged that all three mouse models suggest that this is 
a potentially viable therapeutic intervention, or should 
we be discouraged by the rapid resistance to p53 res-
toration generated in the Eµ-myc model? Perhaps both 
responses are warranted, accompanied by appropri-
ate caveats. It is encouraging that p53 restoration by 
itself appeared to be sufficient to reduce tumor mass 
or to prolong survival in two different lymphoma mod-
els, a sarcoma model, and a hepatocarcinoma model. 
Interestingly, the mechanism of tumor suppression 
by p53 activation appeared to vary (promoting either 
growth arrest/senescence or apoptosis) depending on 
the tumor cell type. The resistance to this intervention 
seen in the Eµ-myc model may reflect the transient (7 
days) reintroduction of p53 function or may reflect some 
unique feature of this tumor model. The relatively per-
sistent cessation of tumor growth in the hepatocarci-
noma model after just 4 days of p53 restoration may 
suggest that some tumor types will not easily generate 
resistance either because of the mechanism of tumor 
suppression in that cell type, the nature of other genetic 
alterations in the tumor type, or the influence of the 
immune system on the tumor suppressive effects (as 
intriguingly suggested by Xue and colleagues).
Simple re-expression of p53 in cells does not seem 
to be sufficient to activate the p53 pathway (Ventura et 
al., 2007; Christophorou et al., 2005. 2006). Rather, the 
transformed environment of tumor cells appears to be 
required to activate the restored p53 protein. In fact, it 
was argued in the Eµ-myc system that p19ARF is the only 
persistent determinant of p53 activation in the tumor 
cells (Christophorou et al., 2005; Martins et al., 2006). 
This total dependence on p19ARF for p53 activation may 
be a reflection of the unusual nature of the Eµ-myc sys-
tem and may not be representative of all tumors or reflect Cell 128, March 9, 2007 ©2007 Elsevier Inc. 839
the situation in human tumors. In addition to activation of 
p14ARF, other signals that activate p53 in human tumors 
(Figure 1) include telomere abnormalities, hypoxia, rep-
licative stress, oxidative stress, and other types of DNA 
damage (Giaccia and Kastan, 1998; Karlseder et al., 
1999). In contrast to human cells, and in particular many 
human tumors, mouse cells have long telomeres. Long 
telomeres in mouse tumors means that these tumor cells 
lack one of the signaling pathways to p53. Interestingly, 
mice lacking p19ARF develop significantly fewer tumors 
when they also contain “humanized” telomeres (short-
ened over generations by genetic deletion of telomer-
ase) (Greenberg et al., 1999). Similarly, although hypoxia 
and oxidative stress may be important stimuli for activat-
ing the p53 pathway during human tumorigenesis, tumor 
development in most mouse models is not dependent 
on these stimuli.
An additional difference between these mouse tumor 
models and human tumors is the lack of dominant-nega-
tive p53 alleles. As noted by Martins et al. (2006) even 
the relapsed tumors in the Eµ-myc mice failed to mutate 
the p53 gene and instead lost the entire p53 allele. This 
is not surprising given that these mouse tumors only 
had one p53 allele to start with. However, p53 is fre-
quently mutated in human tumors, the mutant protein 
is frequently overexpressed because of a prolonged 
half-life, and the mutant overexpressed p53 protein has 
“dominant-inhibitory” and perhaps “gain-of-function” 
biochemical activities. It is possible that the presence of 
these mutant p53 proteins in human tumors could nega-
tively affect the outcome of functional p53 restoration 
depending on how p53 function is restored. Of course, 
if the mechanism by which p53 function is restored is 
through conversion of mutant p53 protein to a functional 
p53 protein (Bykov et al., 2002), then this is no longer a 
concern and, in fact, is a therapeutic benefit.
Regardless of which signal in the tumor cells activates 
p53 following its restoration, the fact that the pathway 
is activated in tumor cells but not normal cells provides 
a potentially important therapeutic selectivity. The goal 
of tumor therapy is to develop interventions that selec-
tively kill tumor cells relative to normal cells. The sug-
gestion that tumor cells, but not normal cells, have a 
cellular environment that activates the p53 pathway 
would create a setting of an advantageous therapeutic 
index. Although genetically malleable mouse models are 
powerful tools for proof of principle, there are numerous 
practical challenges before restoring p53 function in vivo 
in human tumors becomes a reality. However, different 
approaches to achieve this are already in various stages 
of development: gene therapy approaches directly intro-
ducing wild-type p53 genes into tumors are in clinical tri-840 Cell 128, March 9, 2007 ©2007 Elsevier Inc.als (Roth, 2006), the small molecule PRIMA-1 has been 
reported to restore mutant p53 protein to wild-type func-
tion in tissue culture (Bykov et al., 2002), and the small 
molecule nutlin can induce p53 protein (as long as the 
p53 gene itself has not been mutated) in cells by reliev-
ing its inhibition by HDM2 (Vassilev et al., 2004). The 
therapeutic synergy of DNA-damage induction with p53 
restoration in the Eµ-myc model further suggests that 
combinations of standard cytotoxic therapies with any 
of these approaches might add to their effectiveness. 
Although, there are many challenges ahead, these three 
new elegant studies are likely to stimulate new interest in 
developing approaches for restoring p53 function in vivo 
in human tumors.
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